‘It’s Not Going To Be An Easy Market’ – Hikma Talks Strategy For US Biosimilars

As Firm Delivers First-Half Results That Include Sales Growth Of A Tenth

 
• By Dave Wallace

During Hikma’s first-half results call, the company delved into details of its strategic goals for biosimilars, small-molecule generics, injectables, GLP-1s and more.

Red wooden figure in crowd of white wooden figures
Hikma will be just one of many players in US biosimilars • Source: Shutterstock

More from Strategy

More from Business